A systematic review of knowledge, attitudes, and behaviour towards Japanese encephalitis vaccination.

VaccineAug 5, 2026 (epub)
Clinical ResearchInfectious DiseasesPreventive Medicine / Public Health

Rebika Nepali, Catherine King, Julie Leask et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined knowledge, attitudes, and behaviors (KABs) regarding Japanese Encephalitis (JE) vaccination across 26 studies, primarily in endemic countries. It found that adult vaccine recipients generally had low knowledge and awareness of the vaccine, while caregivers exhibited higher levels. The review emphasizes the influence of health workers and community leaders on KABs.

Key findings

  • Adult vaccine recipients had low knowledge and awareness of the JE vaccine.
  • Caregivers demonstrated higher knowledge and awareness compared to adult recipients.
  • Positive attitudes towards JE vaccination were noted, influenced by health workers and community leaders.
  • Barriers to vaccination included cost, time constraints, and vaccine accessibility.

Why it matters

Understanding KABs towards JE vaccination is crucial for developing effective public health strategies. Improving knowledge and addressing barriers can enhance vaccine uptake, ultimately reducing the risk of JE in vulnerable populations.

Source

PubMed · PMID 42556299

Published in Vaccine. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.